A Case of Extensive Alopecia Areata Following Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine with Favorable Outcome

    Yoshihiro Matsuda, Yoshio Kawakami, Masaya Kawamoto, Yoji Hirai, Shin Morizane
    TLDR A woman's hair mostly regrew after hair loss from the COVID-19 vaccine with treatment.
    A 37-year-old woman developed extensive alopecia areata (AA) following the first dose of the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine. Initially presenting with a low-grade fever and coin-sized hair loss, her condition worsened to widespread hair loss. Laboratory tests showed increased serum C-reactive protein and decreased white blood cells. Despite the progression of hair loss, her condition improved significantly with topical corticosteroid therapy, resulting in substantial hair regrowth by day +310, leaving only one bald patch. This case, along with a review of 17 similar cases, suggests that COVID-19 vaccine-related AA may recover favorably with minimal treatment.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

    Similar Research

    6 / 1000+ results